Loibl, S., Untch, M., & Schneeweiss, A. (2019). A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: Clinical results and biomarker analysis of GeparNuevo study. Annals of oncology, 30(8), . https://doi.org/10.1093/annonc/mdz158
Chicago-Zitierstil (17. Ausg.)Loibl, Sibylle, Michael Untch, und Andreas Schneeweiss. "A Randomised Phase II Study Investigating Durvalumab in Addition to an Anthracycline Taxane-based Neoadjuvant Therapy in Early Triple-negative Breast Cancer: Clinical Results and Biomarker Analysis of GeparNuevo Study." Annals of Oncology 30, no. 8 (2019). https://doi.org/10.1093/annonc/mdz158.
MLA-Zitierstil (9. Ausg.)Loibl, Sibylle, et al. "A Randomised Phase II Study Investigating Durvalumab in Addition to an Anthracycline Taxane-based Neoadjuvant Therapy in Early Triple-negative Breast Cancer: Clinical Results and Biomarker Analysis of GeparNuevo Study." Annals of Oncology, vol. 30, no. 8, 2019, https://doi.org/10.1093/annonc/mdz158.